

Supplemental data

Supplemental Table S1. A: Performance of the assays observed in the study according to the RT-PCR CT value.

		Sensitivity (%)*	Specificity (%)
SureScreen IgM	CT\leq25 (<i>n</i> =15)	46.7 (21.5 - 72.0)	100.0
	25<CT<35 (<i>n</i> =15)	73.3 (50.5 - 95.5)	100.0
	CT\geq35 (<i>n</i> =15)	86.7 (69.5 - 100.0)	100.0
	Total (<i>n</i> =45)	68.9 (55.4 - 82.4)	100.0
SureScreen IgG	CT\leq25 (<i>n</i> =15)	6.7 (0.0 - 19.4)	100.0
	25<CT<35 (<i>n</i> =15)	26.7 (4.3 - 49.1)	100.0
	CT\geq35 (<i>n</i> =15)	60.0 (35.2 - 84.8)	100.0
	Total (<i>n</i> =45)	31.1 (17.6 - 44.6)	100.0
SureScreen IgM+IgG	CT\leq25 (<i>n</i> =15)	46.7 (21.5 - 72.0)	100.0
	25<CT<35 (<i>n</i> =15)	73.3 (50.5 - 95.5)	100.0
	CT\geq35 (<i>n</i> =15)	86.7 (69.5 - 100.0)	100.0
	Total (<i>n</i> =45)	68.9 (55.4 - 82.4)	100.0
Szybio IgM	CT\leq25 (<i>n</i> =15)	46.7 (21.5 - 72.0)	100.0
	25<CT<35 (<i>n</i> =15)	66.7 (42.9 - 90.6)	100.0
	CT\geq35 (<i>n</i> =15)	80.0 (59.8 - 100.0)	100.0
	Total (<i>n</i> =45)	64.4 (50.5 - 78.4)	100.0
Szybio IgG	CT\leq25 (<i>n</i> =15)	6.7 (0.0 - 19.4)	100.0
	25<CT<35 (<i>n</i> =15)	26.7 (4.3 - 49.1)	100.0
	CT\geq35 (<i>n</i> =15)	46.7 (21.5 - 72.0)	100.0
	Total (<i>n</i> =45)	26.7 (13.8 - 39.6)	100.0
Szybio IgM+IgG	CT\leq25 (<i>n</i> =15)	46.7 (21.5 - 72.0)	100.0
	25<CT<35 (<i>n</i> =15)	66.7 (42.9 - 90.6)	100.0
	CT\geq35 (<i>n</i> =15)	80.0 (59.8 - 100.0)	100.0

	Total (n=45)	64.4 (50.5 - 78.4)	100.0
Theradiag IgM	CT≤25 (n=15)	33.3 (9.2 - 56.8)	100.0
	25<CT<35 (n=15)	46.7 (21.5 - 72.0)	100.0
	CT≥35 (n=15)	80.0 (59.8 - 100.0)	100.0
	Total (n=45)	53.3 (38.8 - 67.9)	100.0
Alinity IgG	CT≤25 (n=15)	33.3 (9.2 - 56.8)	100.0
	25<CT<35 (n=15)	46.7 (21.5 - 72.0)	100.0
	CT≥35 (n=15)	80.0 (59.8 - 100.0)	100.0
	Total (n=45)	53.3 (38.8 - 67.9)	100.0
Coris COVID19 Ag Respi-Strip	CT≤25 (n=15)	87.0 (70.0 - 100.0)	100.0
	25<CT<35 (n=15)	0.0	100.0
	CT≥35 (n=15)	0.0	100.0
	Total (n=45)	29.0 (15.7 - 42.3)	100.0
Coris COVID19 Ag Respi-Strip & SureScreen IgM+IgG	CT≤25 (n=15)	93.0 (80.1 - 100.0)	100.0
	25<CT<35 (n=15)	73.0 (50.5 - 95.5)	100.0
	CT≥35 (n=15)	87.0 (70.0 - 100.0)	100.0
	Total (n=45)	84.0 (73.3 - 94.7)	100.0
Coris COVID19 Ag Respi-Strip & Szybio IgM+IgG	CT≤25 (n=15)	93.0 (80.1 - 100.0)	100.0
	25<CT<35 (n=15)	67.0 (43.2 - 90.8)	100.0
	CT≥35 (n=15)	80.0 (59.8 - 100.0)	100.0
	Total (n=45)	80.0 (68.3 - 91.7)	100.0
Coris COVID19 Ag Respi-Strip & Alinity IgG	CT≤25 (n=15)	87.0 (70.0 - 100.0)	100.0
	25<CT<35 (n=15)	46.7 (21.5 - 72.0)	100.0
	CT≥35 (n=15)	80.0 (59.8 - 100.0)	100.0
	Total (n=45)	71.0 (57.7 - 84.3)	100.0
Coris COVID19 Ag Respi-Strip & Theradiag IgM	CT≤25 (n=15)	93.0 (80.1 - 100.0)	100.0
	25<CT<35 (n=15)	47.0 (21.7 - 72.3)	100.0
	CT≥35 (n=15)	87.0 (70.0 - 100.0)	100.0
	Total (n=45)	76.0 (63.5 - 88.5)	100.0


*Sensitivity expressed as a percentage with a 95% confidence interval. The sensitivity is evaluated on the cohort of COVID-19 confirmed patients (Table 1). The number of patients tested for sensitivity is shown in the second column.

Supplemental Table S1. B: Performance of the assays observed in the study according to the time from onset of symptoms


		Sensitivity (%)*	Specificity (%)
SureScreen IgM	≤ 7 Days (n=22)	64.0 (43.9 - 84.1)	100.0
	7 - 14 Days (n=14)	71.0 (47.2 - 94.8)	100.0
	≥ 14 Days (n=9)	78.0 (50.9 - 100.0)	100.0
	Total (n=45)	68.9 (55.4 - 82.4)	100.0
SureScreen IgG	≤ 7 Days (n=22)	18.0 (1.9 - 34.1)	100.0
	7 - 14 Days (n=14)	29.0 (5.2 - 52.8)	100.0
	≥ 14 Days (n=9)	67.0 (36.3 - 97.7)	100.0
	Total (n=45)	31.3 (17.6 - 44.6)	100.0
SureScreen IgM+IgG	≤ 7 Days (n=22)	64.0 (43.9 - 84.1)	100.0
	7 - 14 Days (n=14)	71.0 (47.2 - 94.8)	100.0
	≥ 14 Days (n=9)	78.0 (50.9 - 100.0)	100.0
	Total (n=45)	68.9 (55.4 - 82.4)	100.0
Szybio IgM	≤ 7 Days (n=22)	64.0 (43.9 - 84.1)	100.0
	7 - 14 Days (n=14)	64.0 (38.9 - 89.1)	100.0
	≥ 14 Days (n=9)	67.0 (36.3 - 97.7)	100.0
	Total (n=45)	64.4 (50.5 - 78.4)	100.0
Szybio IgG	≤ 7 Days (n=22)	18.0 (1.9 - 34.1)	100.0
	7 - 14 Days (n=14)	21.0 (0.0 - 42.3)	100.0
	≥ 14 Days (n=9)	56.0 (23.6 - 88.4)	100.0
	Total (n=45)	26.7 (13.8 - 39.6)	100.0
Szybio IgM+IgG	≤ 7 Days (n=22)	64.0 (43.9 - 84.1)	100.0
	7 - 14 Days (n=14)	64.0 (38.9 - 89.1)	100.0
	≥ 14 Days (n=9)	67.0 (36.3 - 97.7)	100.0
	Total (n=45)	64.4 (50.5 - 78.4)	100.0
Theradiag IgM	≤ 7 Days (n=22)	50.0 (29.1 - 70.9)	100.0

	7 - 14 Days (<i>n</i> =14)	50.0 (23.8 - 76.2)	100.0
	≥ 14 Days (<i>n</i> =9)	67.0 (36.3 - 97.7)	100.0
	Total (<i>n</i> =45)	53.3 (38.8 - 67.9)	100.0
Alinity IgG	≤ 7 Days (<i>n</i> =22)	45.0 (24.2 - 65.8)	100.0
	7 - 14 Days (<i>n</i> =14)	50.0 (23.8 - 76.2)	100.0
	≥ 14 Days (<i>n</i> =9)	78.0 (50.9 - 100.0)	100.0
	Total (<i>n</i> =45)	53.3 (38.8 - 67.9)	100.0
Coris COVID19 Ag Respi-Strip	≤ 7 Days (<i>n</i> =22)	41.0 (20.4 - 61.6)	100.0
	7 - 14 Days (<i>n</i> =14)	29.0 (5.2 - 52.8)	100.0
	≥ 14 Days (<i>n</i> =9)	0.0	100.0
	Total (<i>n</i> =45)	29.0 (15.7 - 42.3)	100.0
Coris COVID19 Ag Respi-Strip & SureScreen IgM+IgG	≤ 7 Days (<i>n</i> =22)	82.0 (65.9 - 98.1)	100.0
	7 - 14 Days (<i>n</i> =14)	93.0 (79.6 - 100.0)	100.0
	≥ 14 Days (<i>n</i> =9)	78.0 (50.9 - 100.0)	100.0
	Total (<i>n</i> =45)	84.0 (73.3 - 94.7)	100.0
Coris COVID19 Ag Respi-Strip & Szybio IgM+IgG	≤ 7 Days (<i>n</i> =22)	82.0 (65.9 - 98.1)	100.0
	7 - 14 Days (<i>n</i> =14)	86.0 (67.8 - 100.0)	100.0
	≥ 14 Days (<i>n</i> =9)	67.0 (36.3 - 97.7)	100.0
	Total (<i>n</i> =45)	80.0 (68.3 - 91.7)	100.0
Coris COVID19 Ag Respi-Strip & Alinity IgG	≤ 7 Days (<i>n</i> =22)	73.0 (54.4 - 91.6)	100.0
	7 - 14 Days (<i>n</i> =14)	64.0 (38.9 - 89.1)	100.0
	≥ 14 Days (<i>n</i> =9)	78.0 (50.9 - 100.0)	100.0
	Total (<i>n</i> =45)	71.0 (57.7 - 84.3)	100.0
Coris COVID19 Ag Respi-Strip & Theradiag IgM	≤ 7 Days (<i>n</i> =22)	73.0 (54.4 - 91.6)	100.0
	7 - 14 Days (<i>n</i> =14)	79.0 (57.7 - 100.0)	100.0
	≥ 14 Days (<i>n</i> =9)	78.0 (50.9 - 100.0)	100.0
	Total (<i>n</i> =45)	76.0 (63.5 - 88.5)	100.0


*Sensitivity expressed as a percentage with a 95% confidence interval. The sensitivity is evaluated on the cohort of COVID-19 confirmed patients (Table 1). The number of patients tested for sensitivity is shown in the second column.




Supplemental Figure S2: Anti-SARS-CoV-2 IgM & IgG detection using rapid serological diagnosis tests according to RT-PCR CT values. Cycle threshold (CT) values recorded by RT-PCR methods Allplex™ 2019-nCoV Assay Seegene. The boxes represent interquartile ranges with the horizontal line indicating the median CT values and the whiskers showing minimal and maximal CT values. The *p* value was calculated using the Mann-Whitney U test, and compares the distribution of CT values in serological diagnosis tests with positive and negative results.



Supplemental Figure S3. A: Diagnostic test results (%) according to test used and days since onset of symptoms. The diagnostic test results correspond to the proportion of patients with COVID-19 detected by RDTs. Patients in the cohort were divided into three groups according to the days since the onset of symptoms: ≤ 7 days (n=22); 7-14 days (n=14) and ≥ 14 days (n=9). The *p* value was calculated using Exact binomial's test and compares, according to the days since the onset of symptoms, the performance of a combination of antigen and serological RDTs versus antigen and serological RDTs use alone.




Supplemental Figure S3. B: Diagnostic test results (%) according to test used and RT-PCR CT value. The diagnostic test results correspond to the proportion of patients with COVID-19 detected by RDTs. Patients in the cohort were divided into three groups according to RT-PCR CT values: $CT \leq 25$; $25 < CT < 35$ and $CT \geq 35$. The p value was calculated using Exact binomial's test and compares, according to the RT-PCR CT value, the performance of a combination of antigen and serological RDTs versus antigen and serological RDTs use alone.



Anti-SARS-CoV-2 IgM and IgG serological tests

Supplemental Figure S4. A. Anti-SARS-CoV-2 IgM & IgG detection using rapid serological diagnosis tests according to Abbott Alinity Anti-SARS-CoV-2 IgG (S/C). Anti-SARS-CoV-2 IgG serology was performed on the Alinity i Abbott automated system and index of the signal to control values (S/C) were reported. The dotted line indicates the positive threshold (≥ 1.4). The boxes represent interquartile ranges with the horizontal line indicating the median CT value and the whiskers showing minimal and maximal CT values. The p value was calculated using the Mann-Whitney U test and compares the distribution of IgG (S/C) Alinity i Abbott signals in serological diagnosis tests with IgM-/IgG- ; IgM+/IgG- and IgM+/IgG+ results.



Anti-SARS-CoV-2 IgM and IgG serological tests

Supplemental Figure S4. B: Anti-SARS-CoV-2 IgM & IgG detection using rapid serological diagnosis tests according to Theradiag ELISA Anti-SARS-CoV-2 IgM (ratio). Anti-SARS-CoV-2 IgM serology was performed by Theradiag ELISA test and the ratios of the signal were reported. The dotted line indicates the positive threshold (≥ 1.0). The boxes represent interquartile ranges with the horizontal line indicating the median CT value and the whiskers showing minimal and maximal CT values. The p value was calculated using the Mann-Whitney U test and compares the distribution of IgM Theradiag ELISA ratio in serological diagnosis tests with IgM-/IgG- ; IgM+/IgG- and IgM+/IgG+ results.